Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Post by Yeppers12on Jun 01, 2016 12:56am
133 Views
Post# 24921869

Talking from two sides.

Talking from two sides. I thought last quarter they said lending in the healthcare industry was an explosive endeavour. 

However, lending alone is not an explosive enough product line for us as a public company.

Seems like they weren't getting much traction with its original model.  60% QoQ is pretty good but they just made this stock 25 percent more expensive than yesterday. Let me show you:

6.375 million more shares issued.  Plus 2 million dollars out the door for RBP.
With 30 million dollars and 37.2M in shares originally it's, 0.81 cents in net asset back per share. 
So take away what they have for RBP and it's 28M in net asset backing and 43.6M shares outstanding.   That's 64 cents of net asset backing per share. 

I think they should have paid for the acquisition with cash.  It shows the true value of the purchased company.  If you were selling your company, and they offered you shares at a 100% premium to where they were trading, would you take it?  My guess is probably not...  However, if they offered double the shares and doubled the premium...  Optically it looks better but really it's the same as giving the shares at the regular price.
Also, try to find RBP anywhere....  No clue where it came from. 
This seems too shady. 


Bullboard Posts